Inhibrx Biosciences, Inc. (INBX)
84.52
+4.24
(+5.28%)
USD |
NASDAQ |
Nov 06, 16:00
84.95
+0.43
(+0.51%)
After-Hours: 20:00
Inhibrx Biosciences Enterprise Value : 1.291B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 1.291B |
| November 05, 2026 | 1.229B |
| November 04, 2026 | 1.324B |
| November 03, 2026 | 1.241B |
| November 02, 2026 | 1.110B |
| October 30, 2026 | 1.104B |
| October 29, 2026 | 1.132B |
| October 28, 2026 | 1.126B |
| October 27, 2026 | 1.455B |
| October 26, 2026 | 1.352B |
| October 23, 2026 | 1.422B |
| October 22, 2026 | 1.477B |
| October 21, 2026 | 1.493B |
| October 20, 2026 | 1.450B |
| October 19, 2026 | 1.369B |
| October 16, 2026 | 1.370B |
| October 15, 2026 | 1.379B |
| October 14, 2026 | 1.302B |
| October 13, 2026 | 1.329B |
| October 12, 2026 | 1.380B |
| October 09, 2026 | 1.446B |
| October 08, 2026 | 1.413B |
| October 07, 2026 | 1.422B |
| October 06, 2026 | 1.422B |
| October 05, 2026 | 1.439B |
| Date | Value |
|---|---|
| October 02, 2026 | 1.475B |
| October 01, 2026 | 1.489B |
| September 30, 2026 | 1.520B |
| September 29, 2026 | 1.590B |
| September 28, 2026 | 1.544B |
| September 25, 2026 | 1.513B |
| September 24, 2026 | 1.525B |
| September 23, 2026 | 1.524B |
| September 22, 2026 | 1.676B |
| September 21, 2026 | 1.696B |
| September 18, 2026 | 1.657B |
| September 17, 2026 | 1.589B |
| September 16, 2026 | 1.545B |
| September 15, 2026 | 1.602B |
| September 14, 2026 | 1.673B |
| September 11, 2026 | 1.656B |
| September 10, 2026 | 1.687B |
| September 09, 2026 | 1.708B |
| September 08, 2026 | 1.730B |
| September 04, 2026 | 1.831B |
| September 03, 2026 | 1.847B |
| September 02, 2026 | 1.886B |
| September 01, 2026 | 1.882B |
| August 31, 2026 | 1.912B |
| August 28, 2026 | 1.864B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 506.92M |
| Amgen, Inc. | 289.86B |
| Anika Therapeutics, Inc. | 176.07M |
| BioCryst Pharmaceuticals, Inc. | 2.422B |
| Imunon, Inc. | 4.922M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.65M |
| Total Expenses (Quarterly) | 36.65M |
| EPS Diluted (Quarterly) | -2.339 |
| Earnings Yield | -10.50% |
| Normalized Earnings Yield | -10.50 |